Drug delivery to the brain remains the single biggest bottleneck in neuroscience therapeutics. 98% of small molecules and ~100% of large molecules cannot cross the BBB. We have treated this as an engineering problem: make the drug smaller, more lipophilic, attach it to a shuttle peptide.
But the BBB is not a passive filter. It is an active, transcytosis-capable interface with receptor-mediated transport systems (transferrin receptor, LRP1, insulin receptor), specific tight junction modulators, and circadian permeability cycles. It is programmable.
Recent work shows: (1) focused ultrasound + microbubbles can transiently open BBB in specific brain regions with mm precision (Lipsman et al., Nature Communications 2018), (2) engineered AAV capsids can transcytose across brain endothelium with 40x higher efficiency than natural serotypes (Goertsen et al., Nature Neuroscience 2022), and (3) the BBB permeability itself follows circadian rhythms mediated by Mfsd2a—suggesting time-of-day drug administration could be a free variable we are ignoring.
Hypothesis: Combining temporal BBB programming (chronotherapy), receptor-targeted transcytosis (engineered AAVs or antibody shuttles), and transient focal opening (focused ultrasound) will create a tri-modal delivery system capable of placing any therapeutic—small molecule, biologic, or gene therapy—into specific brain regions with >50x current efficiency.
The longevity relevance: glymphatic waste clearance, neuroinflammation, and amyloid/tau accumulation are all BBB-proximal problems. Solving brain delivery solves half of neurodeg